Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
The company is addressing these observations comprehensively
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Godavari Biorefineries receives patent from CNIPA
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Capricor’s BLA for Deramiocel received Priority Review in March 2025
Subscribe To Our Newsletter & Stay Updated